Tim Smith

In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.

An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.

Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.

Oral icotrokinra sustained clearance at scalp, genital, hand/foot, and nail sites through Week 112 in ICONIC-TOTAL, with no rise in adverse event rates.

Check out highlights from news published on Day 2 of the EADV Congress 2026, spanning vitiligo, HS, atopic dermatitis, and more.

Facial and total body repigmentation with upadacitinib kept rising through Week 76 in Viti-Up, with higher responses when NB-UVB was added.

Earlier bimekizumab treatment was tied to higher IHS4-100 rates at 3 years in hidradenitis suppurativa, per post hoc BE HEARD data at EADV 2026.

Tulisokibart met its HiSCR50 primary endpoint at 16 weeks in the phase 2b MK-7240-012 trial assessing moderate to severe hidradenitis suppurativa.

Intralesional BO-112 met its main endpoint in the phase 2b SPOTLIGHT-204 trial, with 61% of patients with resectable basal cell carcinoma responding.

All 3 zumilokibart doses met the EASI-75 primary end point vs placebo at Week 16 in AbbVie's phase 2 APEX Part B atopic dermatitis study.

Dupilumab improved overall CU-Q2oL scores and 22 of 23 items vs placebo at 24 weeks in omalizumab-naive CSU, per a pooled CUPID A and C analysis.

This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.

EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.

The FDA has granted Priority Review to dersimelagon for EPP and XLP, setting a PDUFA date for late February 2027 as LEO Pharma completes its acquisition from Tanabe Pharma.

In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.

FDA accepts Cogent's bezuclastinib NDA for advanced systemic mastocytosis, backed by APEX trial data showing durable, high-rate responses.

Ameluz is now the first FDA-approved photodynamic therapy for a skin cancer, expanding use to superficial basal cell carcinoma (sBCC) in adults.

Phase 3 data show zasocitinib use led to clear or almost clear skin in around 70% of patients by Week 16, setting up an FDA decision in early 2027.

A recap of 7 standout interviews from LEADderm 2026, covering molluscum care, HS pipeline data, precision medicine, and dermatology leadership.

A roundup of dermatology's biggest August headlines, from an FDA approval to conference previews and conversations on equity in care.

At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.

The approval adds brepocitinib (Lisraya), an oral JAK/TYK2 inhibitor, as the first agent specifically studied and approved for dermatomyositis in adults.

LEADderm 2026 brings dermatology leaders to Newport Beach, California, August 29-30, for sessions on leadership, AI in education, and career growth.

Baseline structural damage accounted for most of the variance in placebo-arm radiographic progression across 6 PsA trials.

In the UP-AA trials, both upadacitinib doses outperformed placebo on SALT score ≤20 at week 24 in adults and adolescents with severe alopecia areata.

In the phase 3 VALOR trial, oral brepocitinib 30 mg significantly improved myositis and skin disease activity versus placebo in treatment-refractory dermatomyositis.

Oral socrodeucitinib 12 mg significantly improved PASI 75 and sPGA responses versus placebo at Week 12 in a 125-patient phase 2 trial.

Catch up on July dermatology news: vitiligo and alopecia data, a pipeline discontinuation, psoriasis comparisons, and an FDA sNDA acceptance.

Organon reports pooled phase 3 data showing tapinarof cream (VTAMA) improved atopic dermatitis severity across pediatric and adult age groups by Week 8.

Sanofi has discontinued development of OX40L-targeting amlitelimab for atopic dermatitis, following the heels of Kyowa Kirin's similar rocatinlimab discontinuation.